TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
批准号:
7156937
负责人:
Rafik MARK GHOBRIAL
金额:
$25.3万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2008-12-31
关键词:
AbbreviationsAddressAllograft ToleranceAllograftingAlloimmunizationAntigensAutoradiographyCD4 Positive T LymphocytesCellsChronicClassCoupledCyclosporineCyclosporinsDataDendritic CellsDetectionDevelopmentEngineeringEpitopesEventExhibitsFoundationsGenerationsGenesGrowth FactorHepaticHistocompatibility Antigens Class IIgG1ImmuneImmune responseIn VitroIsoantibodiesLabelLocalizedMajor Histocompatibility ComplexMapsMediatingModelingMononuclearOrganPathway interactionsPeptide MappingPhysiologic pulsePolymerase Chain ReactionPopulationProcessProteinsPulse takingRattusRecombinantsResearch PersonnelSequence AnalysisSiteSpecificitySpliced GenesT-Cell ReceptorT-LymphocyteTestingTransplant RecipientsTransplantationTransplantation ToleranceUrsidae FamilyVenousbasecell typeheart allograftimmunogenicimmunoregulationin vivoinnovationinsightnovelprogramsresponse
中文摘要
我们寻求开发一种临床上适用的策略,以诱导“真正的”移植耐受,
异源嵌合I类MHC分子。我们在大鼠心脏同种异体移植模型中的新发现提供了
这个提议。我们假设:(i)同种异体嵌合诱导的耐受适用于遗传多样的同种异体移植物
受体;(ii)异源嵌合分子通过间接呈递调节免疫应答;(iii)异源嵌合分子通过间接呈递调节免疫应答。
分子产生具有独特功能和TcR同种特异性的独特调节性T细胞。我们建议:
1.确定诱导耐受的不同全嵌合体分子的要求。多重异源嵌合
分子,在不同的菌株组合,将被构建,以确定关键的免疫原性表位中,
I类MHC的多态性区域。在受体上展示供体显性表位的全嵌合分子
将测试I类抗原诱导“真正的”慢性无排斥耐受的能力。
2.异源嵌合[_lh_U]-RT1.aA I类MHC间接提呈的免疫调节作用分析
分子。对同种异体移植耐受性至关重要的免疫原性/隐蔽性自身表位的精细定位将是
_表演。T细胞应答的间接异源嵌合偏离将通过采用宿主或供体型
树突状细胞已经在体外用供体野生型或[Ohh_U]-RT1.Aa分子脉冲。全嵌合蛋白
标记和检测将定位参与异源嵌合体加工和呈递的位点和细胞类型。
将通过以下方法在体内研究“不成熟与成熟”肝DC对同种异体嵌合耐受诱导的需求:
使用造血生长因子Flt 3L功能性刺激DC成熟和同种异体刺激能力,
潜在地消除门静脉内同种异体嵌合体递送后间接诱导的耐受性。
3.间接同种异体识别诱导的调节性T细胞群的特征。我们将
进行调节性T细胞的体内和离体表型和功能表征。异源嵌合世代
调节性T细胞,在这个模型中的一个可能的关键耐受性机制,将在体外探索,通过研究
未成熟的肝树突状细胞,其间接地将同种异体嵌合分子呈递给CD 4 + T细胞。第三,体内
慢性排斥反应分析结合CDR 3分型、免疫组化和序列分析
allochimedc诱导的克隆限制性调节性T细胞将定义独特的T细胞功能特异性,
同种异体嵌合序列对同种异体特异性TcR库的影响>
英文摘要
We seek to develop a clinically applicable strategy to induce "true" transplantation tolerance treated with
allochimeric Class I MHC molecules. Our novel findings in a rat cardiac allograft model provide the foundation of
this proposal. We hypothesize: (i) allochimeric-induced tolerance is applicable to genetically diverse allograft
recipients; (ii) allochimeric molecules modulate the immune response b y indirect presentation; (iii) a Ilochimeric
molecules generate unique regulatory T cells with distinctive functional and TcR allospecificities. We propose:
1. To Define the Requirements of Different AIIochimeric Molecules to Induce Tolerance. Multiple allochimeric
molecules, in different strain combinations, will be constructed to define critical immunogenic epitopes in the
polymorphic regions of class I MHC. AIIochimeric molecules that display donor-dominant epitopes on recipient-
class I antigens will be tested for their ability to induce "true" chronic rejection-free tolerance.
2. To Analyze AIIoimmune Modulation by Indirect Presentation of Allochimeric [_lh___U]-RT1.aA Class I MHC
Molecules. Fine mapping of immunogenic/cryptic self-epitopes that are critical for allograft tolerance will be
_erformed. Indirect allochimeric deviation of T cell responses will be addressed by employing host or donor-type
dendritic cells that have been pulsed in vitro with donor wild-type or [Ohh_U]-RT1.Aa molecules. AIIochimeric protein
labeling and detection will localize the site and cell-type involved in allochimeric processing and presentation.
Requirement of 'immature vs mature' hepatic DC for allochimeric tolerance induction will be investigated in vivo by
functional stimulation of DC matudty and allostimulatory capacity using FIt3L, a heamatopoietic growth factor, to
potentially abrogate indirectly induced tolerance following intra-portal allochimeric delivery.
3. To Characterize the Unique Population of Requlatory T Cells Induced by Indirect Allorecognition. We will
perform in vivo and ex vivo phenotypic and functional characterization of regulatory T cells. Allochimeric generation
of regulatory T cells, a possible key tolerogenic mechanism in this model, will be probed in vitro by studying
immature hepatic dendritic cells that indirectly present allochimeric molecules to CD4+ T cells. Third, in vivo
analysis of chronic rejection coupled with CDR3 spectrotyping, immunoscope and sequence analysis of
allochimedc-induced clonally-restricted regulatory T cells will define unique T cell functional specificities and the
influence of allochimeric sequence on the allospecific TcR repertoire>
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Donor MHC class I peptides in conjunction with self-epitopes induce donor-specific tolerance in a dose-dependent manner but unable to abrogate chronic rejection.
供体 MHC I 类肽与自身表位结合以剂量依赖性方式诱导供体特异性耐受,但无法消除慢性排斥。
DOI:
10.1016/j.transproceed.2005.02.114
发表时间:
2005
期刊:
Transplantation proceedings.
影响因子:
--
作者:
[Semiletova,NV, Shen,X-D, Feldman,DM, Busuttil,RW, Kupiec-Weglinski,JW, Ghobrial,RM]
通讯作者:
Ghobrial,RM
Intragraft gene expression profile associated with the induction of tolerance by allochimeric MHC I in the rat heart transplantation model.
移植物内基因表达谱与大鼠心脏移植模型中异源嵌合 MHC I 诱导耐受相关。
DOI:
10.1002/dvg.20574
发表时间:
2010
期刊:
Genesis (New York, N.Y. : 2000)
影响因子:
--
作者:
[Lisik,Wojciech, Gong,Yongquan, Tejpal,Neelam, Skelton,ThomasS, Bremer,EricG, Kloc,Malgorzata, Ghobrial,RafikM]
通讯作者:
Ghobrial,RafikM
DOI:
10.1016/j.trim.2010.06.009
发表时间:
2010-08
期刊:
Transplant immunology
影响因子:
1.5
作者:
[Skelton TS, Tejpal N, Gong Y, Kloc M, Ghobrial RM]
通讯作者:
Ghobrial RM
Allochimeric molecules and mechanisms in abrogation of cardiac allograft rejection.
同种异体嵌合分子和消除心脏同种异体移植排斥反应的机制。
DOI:
10.1016/j.healun.2011.01.715
发表时间:
2012
期刊:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
影响因子:
--
作者:
[Skelton,TSpencer, Tejpal,Neelam, Gong,Yongquan, Kubiak,JacekZ, Kloc,Malgorzata, Ghobrial,RafikM]
通讯作者:
Ghobrial,RafikM
DOI:
10.1371/journal.pone.0008020
发表时间:
2009-12-02
期刊:
PloS one
影响因子:
3.7
作者:
[Lisik W, Tejpal N, Gong Y, Skelton TS, Ganachari M, Bremer EG, Kloc M, Ghobrial RM]
通讯作者:
Ghobrial RM
共 6 条
4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
-
批准号:10711018
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2023
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
-
批准号:6760900
-
项目类别:
-
资助金额:$26.69万
-
财政年份:2003
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
-
批准号:6999763
-
项目类别:
-
资助金额:$26.06万
-
财政年份:2003
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
-
批准号:6838746
-
项目类别:
-
资助金额:$26.69万
-
财政年份:2003
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
-
批准号:6679033
-
项目类别:
-
资助金额:$13.34万
-
财政年份:2003
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
ADLDT: An Opportunity to Expand the National Donor Pool
-
批准号:7276431
-
项目类别:
-
资助金额:$3.05万
-
财政年份:2002
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
ADLDT: An Opportunity to Expand the National Donor Pool
-
批准号:6660317
-
项目类别:
-
资助金额:$21.04万
-
财政年份:2002
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
ADLDT: An Opportunity to Expand the National Donor Pool
-
批准号:7120588
-
项目类别:
-
资助金额:$28.09万
-
财政年份:2002
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
ADLDT: An Opportunity to Expand the National Donor Pool
-
批准号:7617327
-
项目类别:
-
资助金额:$7.21万
-
财政年份:2002
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
ADLDT: An Opportunity to Expand the National Donor Pool
-
批准号:6945885
-
项目类别:
-
资助金额:$33.71万
-
财政年份:2002
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
ADLDT: An Opportunity to Expand the National Donor Pool
-
批准号:6803451
-
项目类别:
-
资助金额:$23.11万
-
财政年份:2002
-
负责人:Rafik MARK GHOBRIAL
-
依托单位:
海外基金